Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 in adults with COVID-19
NCT04385849Phase 1Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2020
- Primary completion
- Jul 2020
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nogapendekin alfa inbakicept in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Number of Participants With Adverse Events at 3 days. Started Jul 2020; status: terminated.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04385849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385849.